On ECHEMI
Home > Drugs > Suzhou Erye Pharmaceutical Co., Ltd.
Suzhou Erye Pharmaceutical Co., Ltd.
  • Founded in:

    1981-04-13
  • Country:

    China China
  • Address:

    No. 2, Dongqiao Anmin Road, Huangdai Town, Xiangcheng District, Suzhou City
  • Tax NO.:

    913205001377026284
  • Registered Funds:

    300 million yuan
  • Website:

  • Email:

Related Drugs
Acetylspiramycin Capsules
Main ingredients: This product is a mixture of four main components: monoacetylspiramycin II, monoacetylspiramycin III, diacetylspiramycin II and diacetylspiramycin III.
Name Description Content CAS NO. Registered Holders
Monoacetylspiramycin II

It binds to the 50S subunit of the ribosome of sensitive microorganisms, inhibits RNA-dependent protein synthesis and exerts an antibacterial effect

More

It binds to the 50S subunit of the ribosome of sensitive microorganisms, inhibits RNA-dependent protein synthesis and exerts an antibacterial effect

0
Monoacetylspiramycin III

It binds to the 50S subunit of the ribosome of sensitive microorganisms, inhibits RNA-dependent protein synthesis and exerts an antibacterial effect

More

It binds to the 50S subunit of the ribosome of sensitive microorganisms, inhibits RNA-dependent protein synthesis and exerts an antibacterial effect

0
Diacetylspiramycin II

It binds to the 50S subunit of the ribosome of sensitive microorganisms, inhibits RNA-dependent protein synthesis and exerts an antibacterial effect

More

It binds to the 50S subunit of the ribosome of sensitive microorganisms, inhibits RNA-dependent protein synthesis and exerts an antibacterial effect

0
Diacetylspiramycin III

It binds to the 50S subunit of the ribosome of sensitive microorganisms, inhibits RNA-dependent protein synthesis and exerts an antibacterial effect

More

It binds to the 50S subunit of the ribosome of sensitive microorganisms, inhibits RNA-dependent protein synthesis and exerts an antibacterial effect

0
Omeprazole enteric-coated capsules
The main ingredient of this product is omeprazole.
Name Description Content CAS NO. Registered Holders
Omeprazole

Proton pump inhibitor. This product is a fat-soluble weak alkaline drug that is easily concentrated in an acidic environment. After oral administration, it can be specifically distributed in the secretory tubules of the gastric mucosal parietal cells and converted into the active form of sulfenamide in this high-acid environment. Then, it irreversibly combines with the sulfhydryl group of the H, K-ATPase (also known as the proton pump) in the secretory membrane of the parietal cells through a disulfide bond to form a complex of sulfenamide and the proton pump, thereby inhibiting the activity of the enzyme and blocking the final step of gastric acid secretion. Therefore, this product has a strong and lasting inhibitory effect on gastric acid secretion caused by various reasons.

More

Proton pump inhibitor. This product is a fat-soluble weak alkaline drug that is easily concentrated in an acidic environment. After oral administration, it can be specifically distributed in the secretory tubules of the gastric mucosal parietal cells and converted into the active form of sulfenamide in this high-acid environment. Then, it irreversibly combines with the sulfhydryl group of the H, K-ATPase (also known as the proton pump) in the secretory membrane of the parietal cells through a disulfide bond to form a complex of sulfenamide and the proton pump, thereby inhibiting the activity of the enzyme and blocking the final step of gastric acid secretion. Therefore, this product has a strong and lasting inhibitory effect on gastric acid secretion caused by various reasons.

73590-58-6 83
Metformin Glibenclamide Capsules (Ⅰ)
This product is a compound preparation, and its components are: each tablet contains 1.25 mg of glibenclamide and 250 mg of metformin hydrochloride.
Name Description Content CAS NO. Registered Holders
Glibenclamide

Mainly stimulates pancreatic β cells to secrete insulin to produce blood sugar lowering effect

More

Mainly stimulates pancreatic β cells to secrete insulin to produce blood sugar lowering effect

1.25mg 10238-21-8 28
1,1-DIMETHYLBIGUANIDE HYDROCHLORIDE

It can reduce the production of liver glycogen, reduce intestinal absorption of sugar, and improve insulin sensitivity by increasing peripheral sugar uptake and utilization

More

It can reduce the production of liver glycogen, reduce intestinal absorption of sugar, and improve insulin sensitivity by increasing peripheral sugar uptake and utilization

250mg 15537-72-1 55
Oxymatrine for injection
The main ingredient of this product is matrine, and its chemical name is: oxymatrine.
Name Description Content CAS NO. Registered Holders
Ammothamnine

This product can reduce the level of DHBV-DNA in the serum of ducks infected with hepatitis B virus (DHBV), and has a protective effect on toxic liver damage in mice caused by CCL4 and galactosamine.

More

This product can reduce the level of DHBV-DNA in the serum of ducks infected with hepatitis B virus (DHBV), and has a protective effect on toxic liver damage in mice caused by CCL4 and galactosamine.

16837-52-8 11
Oxymatrine for injection
The main ingredient of this product is matrine, and its chemical name is: oxymatrine.
Name Description Content CAS NO. Registered Holders
Ammothamnine

It can reduce the level of DHBV-DNA in the serum of ducks infected with hepatitis B virus (DHBV) and has a protective effect on toxic liver damage in mice caused by CCL4 and galactosamine.

More

It can reduce the level of DHBV-DNA in the serum of ducks infected with hepatitis B virus (DHBV) and has a protective effect on toxic liver damage in mice caused by CCL4 and galactosamine.

16837-52-8 11
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.